Bispecific antibody treatment for relapsed or refractory B-cell lymphoma

This study looks at how well a medicine called glofitamab works and how safe it is for people with a type of blood cancer (diffuse large B-cell lymphoma) that did not respond to first treatment or came back within a year. If you qualify, you may receive glofitamab as part of your care, and the study will track your progress.

This study tests an extra treatment called glofitamab (given as an infusion) after your first therapy has worked well, to help keep the lymphoma from coming back. It is for people with high-risk large B-cell lymphoma, and aims to improve long-term remission.

This trial tests a drug called glofitamab for people with aggressive B-cell lymphomas (like DLBCL or mantle cell lymphoma) that have come back or not responded to standard treatments. The study uses a biopsy during treatment to see how the drug is working, aiming to make treatment more personalized.

This study looks at how well a new drug called glofitamab works in real life for people with a type of lymphoma that has come back or not improved after treatment. It aims to see if the drug is safe and effective outside of a clinical trial setting.

This study tests two ways of giving a new drug called glofitamab — either alone or combined with chemotherapy (GemOx) — for people with aggressive B-cell lymphoma that has returned or not responded to previous treatment. The goal is to find a safer way to give the drug and to see if it helps control the cancer.

This trial tests a new combination approach for people whose aggressive B-cell lymphoma has come back or not responded to treatment. It uses a bispecific antibody (a type of drug that helps immune cells attack cancer cells) followed by CAR-T cell therapy (reprogramming your own immune cells to find and kill cancer), sometimes with a stem cell transplant.